Roche’s Subcutaneous Rituximab Gets Unanimous Recommendation From Fda Advisory Committee

In a press release, Roche announced today that FDA’s Oncologic Drug Advisory Committee has voted unanimously in favor of a subcutaneous injection of rituximab for the treatment of certain blood cancers, including previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), relapsed or refractory low grade or follicular lymphoma, and previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL). A new co-formulation of the same monoclonal antibody as in intravenous Rituxan® and hyaluronidase enzyme, Roche’s product is marketed under the MabThera® SC brand in Europe and many other countries outside the U.S. The FDA’s decision on approval is expected by June 26, 2017.

 

The post Roche’s Subcutaneous Rituximab Gets Unanimous Recommendation From Fda Advisory Committee appeared first on Big Molecule Watch.